LAXMIDENTL Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹66 Cr
verified against source
Revenue YoY
7.1%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laxmi Dental delivered Q3 FY26 revenue of ₹66 crores, up 7.1% YoY to ₹61.7 crores, but missed expectations amid a challenging macro environment. US tariffs at 50% (up from pre-existing rates) compressed EBITDA margins by ~150 bps on a full-quarter basis, with management acknowledging that without tariff headwinds growth would have been materially stronger. Gross margin held at 69.5% despite scanner sales mix (lower-margin strategic enabler). A one-time exceptional charge of ₹5.8 crores from new labor code compliance dented PAT. International lab grew robustly at 25% YoY while domestic lab and aligner businesses underperformed due to NRI patient inflow shortfall and competitive pricing. Management flagged January 2026 recovery trends across segments and expects Q4 to be a "strong exit quarter." Forward guidance targets 20-25% international growth and 18-20% EBITDA margins in FY27 assuming normalized tariff environment (now reduced to 25%) and no external surprises. Key risks include tariff re-escalation, aligner pricing pressure, and currency headwinds from dollar appreciation on raw material costs.
Colored figures show movement against the previous available record.
Guidance to track
- Management stated internal aspiration to return to 17.5% EBITDA (FY25 level) and move toward 20% range, contingent on normalized tariff environment (no surprises), ESOP costs halving from second year onwards, and scanner mix stabilization.
- CEO confirmed already delivering ~25% growth in international markets; expects this 20-25% range to be achievable in FY27 provided no additional tariff disruptions emerge from the US.
- Management expects robust YoY performance in both domestic lab and aligner businesses in Q4, citing positive January 2026 trends and new strategic initiatives implemented in Q3.
- Target to increase company-level digital penetration from 79% to 90%, described as the 'pivoting point' for potential 100% digital lab transition, with both scanner sales and 'scan as a service' models being deployed.
Risks flagged
- China faces 34% tariffs while Laxmi Dental moved from 50-57% down to 25%. Management acknowledged they remain more expensive than Chinese competitors. If tariffs increase again, customer attrition could recur, impacting both revenue and profitability targets.
- Q3 underperformance attributed partly to lower US NRI patient inflows in Gujarat/western India belt (45-50% of domestic business). This exposes the business to immigration/travel policy changes and currency-driven demand shifts beyond management control.
- Management claimed pricing pressure is 'trending towards normalcy' but provided no quantitative data. The aligner segment (₹16.4 crores, flat YoY) remains under competitive stress, and this claim cannot be verified until Q4 results confirm volume recovery.
- When asked whether scanners sold to dentists can be used to send scans to competitor labs, management gave a nuanced answer: minimum volume commitment required but scans can be sent elsewhere above threshold. This competitive risk to the lab network was not proactively raised by management.
Key quotes
- We had to let go of few customers where the tariff situation could not allow us to give them the pricing that they needed. So that was also one of the reasons especially in the US where even if it's at 20-25% growth we could have grown much stronger there if not for the tariff situation.
- We have done some soft launches on the AI Dent part and also internally we are implementing a lot of AI which is still in pilot phases but we believe we have seen very very good potential... we are very excited on what we are creating.
- Unfortunately for us this is the first year of being listed that the year it is right now but having said that we are still very confident internally as management that we are absolutely raised a focus on what we do in dentistry and we truly believe that we have created leadership position.
Research modules